Carterra and AstraZeneca have initiated a research collaboration focused on advancing lab-in-the-loop drug discovery. This effort combines scientific and technical expertise to integrate laboratory systems, software, and data infrastructure with AI-driven discovery workflows. The collaboration addresses a growing industry interest in this model, which involves AI proposing drug candidates, followed by wet-lab experiments generating data for validation, and the data informing subsequent AI design. This approach is seen as a key shift in antibody discovery, as highlighted by recent reports from Leerink Partners and William Blair. The model emphasizes the need for consistent and comparable experimental data to effectively apply AI in drug discovery.
At the core of this collaboration is the development of hardware and software designed to facilitate a connected, AI-enabled discovery loop. Carterra’s engineering and software teams are working with AstraZeneca’s scientists and automation experts to create laboratory systems capable of generating standardized data at scale. The resulting data will be directly usable in AI and machine learning workflows. This initiative responds to a recognized barrier in the field – the need for consistent experimental data across large-scale experiments.